CN101820884B - 用于治疗轻度认知缺损的吩噻嗪化合物 - Google Patents

用于治疗轻度认知缺损的吩噻嗪化合物 Download PDF

Info

Publication number
CN101820884B
CN101820884B CN2008801031955A CN200880103195A CN101820884B CN 101820884 B CN101820884 B CN 101820884B CN 2008801031955 A CN2008801031955 A CN 2008801031955A CN 200880103195 A CN200880103195 A CN 200880103195A CN 101820884 B CN101820884 B CN 101820884B
Authority
CN
China
Prior art keywords
mtc
treatment
scopolamine
memory
rivastigmine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801031955A
Other languages
English (en)
Chinese (zh)
Other versions
CN101820884A (zh
Inventor
克劳德·M·威希克
多米尼克·V·哈巴兰
杰诺特·里德尔
塞雷娜·戴亚纳
伊丽莎白·A·戈特曼
戴蒙·J·威希克
艾利森·D·默里
罗杰·T·斯塔夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wista Laboratories Ltd
Original Assignee
Wista Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wista Laboratories Ltd filed Critical Wista Laboratories Ltd
Publication of CN101820884A publication Critical patent/CN101820884A/zh
Application granted granted Critical
Publication of CN101820884B publication Critical patent/CN101820884B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2008801031955A 2007-06-19 2008-06-17 用于治疗轻度认知缺损的吩噻嗪化合物 Active CN101820884B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94500607P 2007-06-19 2007-06-19
US60/945,006 2007-06-19
PCT/GB2008/002066 WO2008155533A2 (en) 2007-06-19 2008-06-17 Phenothiazine compounds for treating mild cognitive impairment

Publications (2)

Publication Number Publication Date
CN101820884A CN101820884A (zh) 2010-09-01
CN101820884B true CN101820884B (zh) 2013-08-28

Family

ID=39943003

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801031955A Active CN101820884B (zh) 2007-06-19 2008-06-17 用于治疗轻度认知缺损的吩噻嗪化合物

Country Status (16)

Country Link
US (1) US9211294B2 (https=)
EP (1) EP2167095B1 (https=)
JP (1) JP5725605B2 (https=)
CN (1) CN101820884B (https=)
AU (1) AU2008265045B2 (https=)
BR (1) BRPI0813670A2 (https=)
CA (1) CA2690746C (https=)
DK (1) DK2167095T3 (https=)
ES (1) ES2739546T3 (https=)
HR (1) HRP20191513T1 (https=)
HU (1) HUE045460T2 (https=)
MY (1) MY177001A (https=)
PL (1) PL2167095T3 (https=)
PT (1) PT2167095T (https=)
SI (1) SI2167095T1 (https=)
WO (1) WO2008155533A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
CA3027974C (en) * 2007-10-03 2022-03-15 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines
US8828986B2 (en) 2011-04-20 2014-09-09 Prosetta Antiviral Inc. Antiviral compounds
CN102958525B (zh) 2010-04-30 2017-05-24 普罗瑟塔抗病毒股份有限公司 抗病毒化合物
EA025033B1 (ru) * 2011-02-11 2016-11-30 Уиста Лэборэтэриз Лтд. Диаминиевые соли фенотиазина и их применение
EP2951149B1 (en) * 2013-01-30 2018-10-10 Ecolab USA Inc. Hydrogen sulfide scavengers
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
WO2016133995A1 (en) * 2015-02-17 2016-08-25 Arizona Board Of Regents On Behalf Of Arizona State University Phenothiazine analogues as mitochondrial therapeutic agents
KR102592614B1 (ko) * 2016-07-25 2023-10-24 위스타 레보레이토리스 리미티드 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage)
GB201614834D0 (en) * 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
DK3826639T3 (da) 2018-07-26 2024-09-23 Wista Lab Ltd Optimeret dosering af diaminophenothiaziner i populationer
MY209608A (en) * 2019-04-10 2025-07-24 Genting Taurx Diagnostic Centre Sdn Bhd Adaptive neurological testing method
GB201909493D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Therapeutic interactions
GB201909454D0 (en) 2019-07-01 2019-08-14 Wista Lab Ltd Enhancers
GB201909506D0 (en) 2019-07-02 2019-08-14 Wista Lab Ltd Synaptopathies
WO2023232764A1 (en) 2022-05-31 2023-12-07 Wista Laboratories Ltd. Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds
AU2024231880A1 (en) 2023-03-03 2025-09-11 Taurx Therapeutics Management Ltd. Diaminophenothiazine for the treatment of microvascular brain disease disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
GB0017060D0 (en) * 2000-07-11 2000-08-30 Hunter Fleming Ltd Production, stabilisation and use of reduced forms of pharmaceutical compounds
GB0101049D0 (en) 2001-01-15 2001-02-28 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
WO2004087160A1 (en) * 2003-04-03 2004-10-14 Prana Biotechnology Ltd Treatment of neurological conditions
AU2005286235C1 (en) 2004-09-23 2013-08-22 TauRx Therapeutics Management Ltd Methods of chemical synthesis and purification of diaminophenothiazinium compounds including Methylthioninium Chloride (MTC)
CN101084204B (zh) * 2004-09-23 2012-12-05 卫思道制药有限公司 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法
WO2006091728A2 (en) * 2005-02-24 2006-08-31 The Trustees Of The University Of Pennsylvania Microtubule stabilizing compounds and methods of their use
EP2013191B3 (en) 2006-03-29 2019-02-27 Wista Laboratories Ltd. 3,7-diamino-10h-phenothiazine salts and their use
MY162640A (en) * 2006-03-29 2017-06-30 Wista Lab Ltd Thioninium compounds and their use
PL2004155T3 (pl) 2006-03-29 2018-08-31 Wista Laboratories Ltd. Inhibitory agregacji białek
DK3121169T3 (da) * 2006-07-11 2022-02-28 Wista Lab Ltd Fremgangsmåder til syntese og/eller oprensning af diaminophenothiaziniumforbindelser

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
《Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats》;Narriman Lee Callaway,Penny D.Riha,Kathrym M.Wrubel.et.al;《Neuroscience Letters》;20021031;第332卷(第2期);83-86 *

Also Published As

Publication number Publication date
US9211294B2 (en) 2015-12-15
BRPI0813670A2 (pt) 2014-12-30
ES2739546T3 (es) 2020-01-31
JP2010530403A (ja) 2010-09-09
EP2167095B1 (en) 2019-05-29
PT2167095T (pt) 2019-08-06
HRP20191513T1 (hr) 2019-11-29
PL2167095T3 (pl) 2019-11-29
US20100184752A1 (en) 2010-07-22
JP5725605B2 (ja) 2015-05-27
CA2690746C (en) 2018-01-02
WO2008155533A3 (en) 2009-02-19
CA2690746A1 (en) 2008-12-24
AU2008265045B2 (en) 2014-02-27
DK2167095T3 (da) 2019-07-29
EP2167095A2 (en) 2010-03-31
CN101820884A (zh) 2010-09-01
AU2008265045A1 (en) 2008-12-24
MY177001A (en) 2020-09-01
WO2008155533A2 (en) 2008-12-24
SI2167095T1 (sl) 2019-09-30
HUE045460T2 (hu) 2019-12-30

Similar Documents

Publication Publication Date Title
CN101820884B (zh) 用于治疗轻度认知缺损的吩噻嗪化合物
KR102654569B1 (ko) 외상 후 스트레스 장애의 치료를 위한 제제
CN107810002B (zh) 左乙拉西坦的延时释放药物组合物
JP7642735B2 (ja) アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物
US11826321B2 (en) Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions
CN114072945A (zh) 用于治疗精神障碍、行为障碍、认知障碍的新型药物组合物和方法
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
US10736894B2 (en) Methods of treating developmental syndromes with PDE10A inhibitors
EP2286810A1 (en) Pharmaceutical composition for treatment of fibromyalgia
Jillani et al. Atomoxetine for the treatment of ADHD in incarcerated adolescents
CN114126622A (zh) 无色甲基硫堇鎓的治疗相互作用
JP2018505899A (ja) ストレス誘発性ｐ−ｔａｕを低下させるトリアゾロピリジン及びトリアゾロピリミジン
CN114072154B (zh) 用于治疗精神障碍的加波沙朵和锂的组合物
JP2019519480A (ja) パーキンソン病患者において転倒を低減するためのアセチルコリンエステラーゼ阻害剤およびイダロピルジンの使用
HK1136965B (en) Phenothiazine compounds for treating mild cognitive impairment
HK1136965A (en) Phenothiazine compounds for treating mild cognitive impairment
ES2747993T3 (es) Composiciones farmacéuticas de liberación prolongada de levetiracetam
Yoon et al. Paliperidone in the treatment of delirium: results of a prospective open-label pilot trial
HK40052880A (en) Extended release pharmaceutical compositions of levetiracetam
JP2011520905A (ja) 向知性剤としてのムスカリンアゴニスト
HK1252154B (zh) 左乙拉西坦的延时释放药物组合物
Althobaiti Effects of Modulating Glutamate Homeostasis in Methamphetamine and Alcohol Co-Abuse: Potential Therapeutic Targets

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant